Supplementary Digital Content

Table S1. Tuberculosis Risk Using 6 Month HAART Cut-off-Marginal Structural Model

With Varying Inverse Probability Weights

Characteristic	ITT Analysis		ITT Analysis	
	IPW truncated at 5 <sup>th</sup> and 95 <sup>th</sup>		IPW truncated at 10 <sup>th</sup> and 90 <sup>th</sup>	
	percentile		percentile	
	aOR <sup>a</sup>	95% CI	aOR <sup>a</sup>	95% CI
HAART status				
Not on HAART	Ref		Ref	
<u>&lt;</u> 6 months	0.71	0.34, 1.47	0.71	0.35, 1.46
>6 months	0.30	0.17, 0.53	0.30	0.17, 0.52

aOR, adjusted odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; ITT, intention-to-treat; IPW, inverse probability weight

<sup>a</sup>Adjusted for baseline age, sex, race, Non-US or Canadian born, injection drug use as HIV transmission factor, baseline CD4+ count, baseline HIV-1 viral load, time since study entry (months), and year of enrollment.

Supplementary Digital Content

Table S2. Tuberculosis Risk Using 6 Month HAART Cut-off-Marginal Structural Model With

Varying Inverse Probability Weights

Characteristic	As-Treated Analysis IPW truncated at 5 <sup>th</sup> and 95 <sup>th</sup> percentile		As-Treated Analysis IPW truncated at 10 <sup>th</sup> and 90 <sup>th</sup> percentile	
	aOR <sup>a</sup>	95% CI	aORª	95% CI
HAART status				
Not on HAART	Ref		Ref	
<u>≺</u> 6 months	0.83	0.39, 1.75	0.83	0.39, 1.75
>6 months	0.12	0.06, 0.25	0.13	0.06, 0.25

aOR, adjusted odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy; IPW, inverse probability weight

<sup>a</sup>Adjusted for baseline age, sex, race, Non-US or Canadian born, injection drug use as HIV transmission factor, baseline CD4+ count, baseline HIV-1 viral load, time since study entry (months), and year of enrollment.